Makoto Takenaga
Okayama University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Makoto Takenaga.
American Heart Journal | 1996
Kohji Kobayashi; Kazuo Kitamura; Naoteru Hirayama; Haruhiko Date; Takafumi Kashiwagi; Ippei Ikushima; Yuhji Hanada; Yoshitatsu Nagatomo; Makoto Takenaga; Tadashi Ishikawa; Takuroh Imamura; Yasushi Koiwaya; Tanenao Eto
Adrenomedullin has a potent vasodilating effect comparable to that of calcitonin gene-related peptide. To investigate the pathophysiologic role of endogenous adrenomedullin, we determined sequentially the plasma adrenomedullin level in 15 consecutive patients with acute myocardial infarction (AMI). Plasma adrenomedullin was higher immediately after the onset of AMI and decreased gradually; plasma levels during the 3-week period after the AMI were higher than plasma levels in 15 healthy control subjects (p < 0.001), with higher levels in patients with congestive heart failure than in patients without congestive heart failure throughout the period of the study (p < 0.05). Plasma adrenomedullin was positively correlated with pulmonary capillary wedge pressure, pulmonary arterial pressure, right atrial pressure, and heart rate in the early stage of AMI. These findings suggest that the elevation of plasma adrenomedullin is related to the retention of body fluid volume, the enhancement of sympathetic activity, and/or the elevation of pressure in pulmonary vascular beds. Adrenomedullin may act against excessive vasoconstrictors increased in AMI.
American Heart Journal | 1996
Kohji Kobayashi; Kazuo Kitamura; Takuma Etoh; Yoshitatsu Nagatomo; Makoto Takenaga; Tadashi Ishikawa; Takuroh Imamura; Yasushi Koiwaya; Tanenao Eto
Adrenomedullin is a potent vasodilator peptide and occurs in circulating blood of human beings and experimental animals. Because it is produced in intact aorta of rats and in cultured vascular endothelial cells, adrenomedullin seems to participate in regulation of local vascular tone. To determine the pathophysiological roles of adrenomedullin, we investigated its plasma concentrations in 49 patients with heart failure. Plasma adrenomedullin levels increased significantly with advancing severity of the disease (New York Heart Association functional class I, 4.1 +/- 1.0; II, 5.6 +/- 1.6; III, 6.4 +/- 0.8; IV, 13.2 +/- 6.8 (fmol/l). Plasma adrenomedullin was correlated with pulmonary artery pressure (r = 0.44, p = 0.0114) and pulmonary capillary wedge pressure (r = 0.53, p = 0.0002). These findings indicate that adrenomedullin may play some important role in the pathophysiologic makeup of heart failure by its vasodilating effects against the concomitant exaggeration of humor pressor agents such as catecholamine and the renin-angiotensin system. Hemodynamic changes in pulmonary circulation may have some influence on the increased synthesis and secretion of plasma adrenomedullin in chronic congestive heart failure.
Circulation Research | 1995
Makoto Takenaga; Hiromu Kawasaki; Akihiko Wada; Tanenao Eto
The role of calcitonin gene-related peptide (CGRP)-containing vasodilator nerves in acetylcholine chloride (ACh)-induced vasodilation was studied in the perfused mesenteric vascular bed isolated from the rat. Bolus infusions of ACh at smaller doses (0.1 and 1 nmol) produced rapid and short-lived vasodilation. However, larger doses (10 and 100 nmol) of ACh caused a rapid and subsequent long-lasting vasodilator response in which the duration of vasodilation was prolonged in a concentration-dependent manner. Pretreatment with capsaicin (1 mumol/L for 20 minutes) significantly shortened the duration of vasodilator response to ACh but did not affect the initial rapid phase of ACh-induced vasodilation. Chemical removal of the vascular endothelium by perfusion with sodium deoxycholate (1.75 to 1.80 mg/mL) for 30 seconds and subsequent treatment with N omega-nitro-L-arginine (100 mumol/L) to inhibit nitric oxide synthesis abolished the initial rapid vasodilator action of ACh at any given concentration. However, in the same preparation, increasing concentrations (from 1 to 1000 nmol) of ACh produced only the long-lasting vasodilator responses in a concentration-dependent manner. This long-lasting vasodilator response to ACh infusion was abolished by capsaicin pretreatment (1 mumol/L), human CGRP[8-37] (CGRP receptor antagonist, 1 mumol/L), and atropine (muscarinic ACh receptor antagonist, 1, 10, and 100 nmol/L) but not by hexamethonium (nicotinic ACh receptor antagonist, 1 and 10 mumol/L). In the preparations without endothelium, the bolus infusion of ACh (300 nmol for 30 seconds) evoked a long-lasting vasodilation and release of CGRP-like immunoreactivities into the perfusate.(ABSTRACT TRUNCATED AT 250 WORDS)
European Journal of Pharmacology | 1999
Makoto Takenaga; Hiromu Kawasaki
The role of perivascular calcitonin gene-related peptide (CGRP)-containing nerves in the modulation of adrenergic nerve-mediated vasoconstrictions was studied in the rat perfused mesenteric vascular bed. A frequency-dependent vasoconstriction induced by periarterial nerve stimulation (1-6 Hz) of the bed was significantly potentiated by perfusion of 1 microM CGRP-(8-37) (CGRP receptor antagonist) or to a similar extent after treatment with 500 nM capsaicin. In the preparations treated with capsaicin, CGRP-(8-37) caused a small potentiation of periarterial nerve stimulation-induced vasoconstriction. Exogenous CGRP (0.1-1 nM) concentration-dependently attenuated the augmented vasoconstriction in response to periarterial nerve stimulation after treatment with capsaicin. However, exogenous CGRP (1 nM) did not attenuate the periarterial nerve stimulation-induced vasoconstriction in the bed untreated with capsaicin. These results suggest that endogenous CGRP, which is released from CGRP-containing nerves, suppresses the adrenergic nerve function involved in mechanisms regulating the tone of resistant blood vessels.
Cancer | 1991
Takuroh Imamura; Kazuo Tamura; Makoto Takenaga; Yoshitatsu Nagatomo; Tadashi Ishikawa; Susumu Nakagawa
Ten patients with malignant pericardial effusion were treated with intrapericardial injection of OK‐432 (penicillin‐treated and heat‐treated lyophilized powder of the substrain of Streptococcus pyogenes A3). After intrapericardial insertion of a catheter, a maximal volume of pericardial fluid was withdrawn with cytologic confirmation of malignancy. Five or 10 Klinische Einheit (KE) (KE is a unit used to express the strength of a preparation) of OK‐432 diluted in 20 ml of saline was injected into the pericardial space in seven and three patients, respectively. It was repeated in case of reaccumulation. Seven patients were treated only once and the remaining three required a second treatment. Complete control of pericardial effusion was achieved in all patients for an average of 329 days (range, 54 to 790 days). Fever and chest pain were experienced in six and five patients, respectively, but were controlled with antipyretics. Two of three patients who received 10 KE of OK‐432 experienced hypotension that was successfully controlled with vasopressor drugs with or without reaspiration of pericardial fluid. Rapid reactive reaccumulation of the pericardial fluid was thought to be a cause of hypotension. A follow‐up computed tomography (CT) scan was performed in seven patients and a thickened pericardium was noticed in five; no patients had constrictive pericarditis. These results suggest that intrapericardial administration of 5 KE of OK‐432 is an effective and safe treatment for malignant pericardial effusion.
Archive | 2000
Hiromu Kawasaki; Makoto Takenaga
Resistance blood vessels play an important role in maintenance of blood pressure and regulation of tissue blood flow (Mulvany and Aalkjaer, 1990). Resistance vascular tone is mainly controlled by sympathetic adrenergic nerves through the release of the neurotransmitter norepinephrine (Mulvany and Aalkjaer, 1990). Indeed, electrical field stimulation (EFS) of perivascular nerves in blood vessels isolated from various species evokes vasoconstriction, which is blocked by a-adrenoceptor antagonists (prazosin), adrenergic neuron blockers (guanethidine), and the neurotoxin tetrodotoxin (TTX). However, EFS of precontracted blood vessels isolated from various species causes vasodilation (Bevan and Bryden, 1987), which can be abolished by TTX but not by 13-adrenoceptor antagonists or muscarinic cholinoceptor antagonists (atropine). These results suggest nonadrenergic, noncholinergic (NANC) vasodilator innervation. However, these studies have been performed on relatively large arteries and/or conduit arteries in vitro, and evidence of NANC innervation and NANC neurotransmitter in small arteries and/or resistance arteries is scarce.
Journal of Cardiology | 2001
Hisamitsu Onitsuka; Takuroh Imamura; Nobuhide Miyamoto; Yoshisato Shibata; Takafumi Kashiwagi; Takao Ayabe; Junji Kawagoe; Matsuda J; Tetsunori Ishikawa; Unoki T; Makoto Takenaga; Takashi Fukunaga; Susumu Nakagawa; Yasushi Koiwaya; Tanenao Eto
Journal of Pharmacology and Experimental Therapeutics | 1998
Hiromu Kawasaki; Makoto Takenaga; Hiroaki Araki; Kojirou Futagami; Yutaka Gomita
Clinical Cardiology | 1999
Takuma Etoh; Johji Kato; Makoto Takenaga; Takuroh Imamura; Kazuo Kitamura; Yasushi Koiwaya; Tanenao Eto
Cardiovascular Ultrasound | 2013
Masashi Yamaguchi; Toshihiro Tsuruda; Yuki Watanabe; Hisamitsu Onitsuka; Kuniko Furukawa; Takeshi Ideguchi; Junji Kawagoe; Tetsunori Ishikawa; Johji Kato; Makoto Takenaga; Kazuo Kitamura